antithrombotics

Abciximab - Apixaban - Bivalirudin - Coumadin - Dabigatran - Deltaparin - Dicoumarol - Edoxaban - Eptifibatide - Fondaparinux - Fraxiparin - Heparin - Hirudin - Idraparinux - Reviparin - Rivaroxaban - Tirofiban - UFH - Wafarin - Warfarin - Ximelagatran      

Select
Display
Trial Studied trt Control trt patientstagsNCTROB Result

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009apixabanplaceboNCT00313300Exploratory negative
APPRAISE-1 (2.5 mg bid), 2009apixabanplaceboNCT00313300 negative
APPRAISE 2, 2011apixabanplaceboNCT00831441Low risk of bias negative
APPRAISE japan ongoing apixabanplaceboNCT00852397Exploratory ongoing
argatroban
ARGAMI-2, 1998Argatrobanheparin -
aspirin
ATACS-pilot, 1990aspirincontrolnegative
VA-pilotaspirinplacebonegative
VA-main, 1983aspirinplacebosuggesting
RISC, 1990aspirinplacebosuggesting
ALDUSA-pilotaspirinplacebonegative
Théroux, 1988aspirinplacebosuggesting
Canadian (Aspirin vs PBO), 1985aspirinplacebo -
Canadian (Aspirin + sulfinpyrazone), 1985aspirin + sulfinpyrazoneplacebonegative
atopaxar
LANCELOT ACSatopaxarplaceboExploratory -
J-LANCELOT, 2010atopaxarplaceboExploratory -
bivalirudin
ACUITY (biva alone vs hep+aGP2b3a), 2006bivalirudinheparin + GP2b3a inhibitorsNCT00093158suggesting
ACUITY (biva+aGP2b3a vs hep+aGP2b3a), 2006bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsNCT00093158negative
PROTECT-TIMI 30, 2006bivalirudineptifibatide + heparinNCT00250471Exploratory -
HERO, 1997bivalirudinheparinExploratory suggesting
BAT (Bittl), 1995bivalirudinheparinLow risk of bias suggesting
ACUITY (sub groups PCI, bivalirudin alone) importé, 2007bivalirudinheparin + GP2b3a inhibitorssuggesting
ACUITY (sub groups PCI, bivalirudin +aGP2b3a) importé, 2007bivalirudin + GP2b3a inhibitorsheparin + GP2b3a inhibitorsnegative
clopidogrel
CURE (PCI sub study), 2001clopidogrelplaceboExploratory -
CURE, 2001clopidogrel + aspirinaspirinsuggesting
CURRENT OASIS 7 (clopidogrel), 2010clopidogrel high-dose regimenclopidogrel standard-doseNCT00335452Low risk of bias negative
coumadin
ASPECT-2 (coumadin+asp vs asp), 2002coumadincontrol (on top of aspirin)suggesting
ASPECT-2 (coumadin vs aspirin), 2002coumadinaspirinsuggesting
dalteparin
FRISC (long term), 1996dalteparinplacebo (on top of aspirin)Exploratory suggesting
FRIC prolonged treatment phase (LWMH vs PBO), 1997dalteparinplacebo (on top of aspirin)negative
FRISC (short term), 1996dalteparinplacebo (on top of aspirin)Low risk of bias -
FRIC (acute phase LMWH vs UFH), 1997dalteparinUFH (on top of aspirin)Exploratory negative
dipyridamol
Prandoni, 1991aspirin + dipyridamolplacebonegative
Efegatran
Klootwijk, 1999EfegatranheparinExploratory -
enoxaparin
RESCUEenoxaparinunfractionated heparinNCT00077818 -
EVET, 2005enoxaparintinzaparinsuggesting
ESSENCE, 1997enoxaparinUFH (on top of aspirin)suggesting
TIMI 11 B (short term), 1998enoxaparinUFH (on top of aspirin)suggesting
SYNERGY, 2005enoxaparinUFH (on top of aspirin)NCT00043784negative
INTERACT, 2006enoxaparinUFH (on top of aspirin)suggesting
TIMI 11 B (long term), 1998enoxaparinUFH (on top of aspirin)negative
fondaparinux
PENTUA, 2004fondaparinuxenoxaparin -
OASIS 5, 2006fondaparinuxenoxaparinNCT00139815 -
hirudin
HIT-4, 1999HirudinheparinExploratory -
TIMI 9B, 1996HirudinheparinRisk of bias -
GUSTO IIB, 1996HirudinheparinRisk of bias -
OASIS pilot, 1997HirudinheparinExploratory -
HELVETICA (Serruys), 1995HirudinheparinLow risk of bias -
OASIS 2, 1999HirudinheparinLow risk of bias -
OASIS, 1997HirudinheparinRisk of bias -
inogatran
TRIM, 1997InogatranheparinExploratory -
nadroparin
FRAXIS (6days), 1998nadroparinUFH (on top of aspirin)Low risk of bias negative
FRAXIS (14 days), 1998nadroparinUFH (on top of aspirin)negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009otamixabanunfractionated heparinNCT00317395Exploratory suggesting
prasugrel
TRILOGY ACS (overall population), 2012prasugrelclopidogrelNCT00699998Low risk of bias negative
TRITON-TIMI 38, 2007prasugrelclopidogrelNCT00097591Low risk of bias suggesting
ACAPULCO ongoing prasugrelclopidogrel ongoing
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011rivaroxaban 2.5mgplaceboNCT00809965Low risk of bias suggesting
ATLAS ACS 2 - TIMI 51 (5mg), 2011rivaroxaban 5mgplaceboNCT00809965suggesting
sulfinpyrazone
Canadian (sulfinpyrazone alone), 1985sulfinpyrazoneplacebo -
ticagrelor
PLATO, 2009ticagrelorclopidogrelNCT00391872Low risk of bias suggesting
DISPERSE-2 (90mg), 2007ticagrelorclopidogrelExploratory negative
ticlopidine
STAI, 1990ticlopidinecontrolsuggesting
Florida UAticlopidineplacebonegative
trapidil
Modenatrapidilplacebosuggesting
triflusal
TIM, 2000triflusalaspirin -
Plaza, 1993triflusalplacebosuggesting
UFH
Holdright, 1994UFHcontrol (on top of aspirin)negative
RISC (heparin+aspirin vs ASP), 1990UFHcontrol (on top of aspirin)negative
Theroux (heparin+ASP vs ASP), 1988UFHcontrol (on top of aspirin)suggesting
ATACS (Cohen), 1994UFH, warfarincontrol (on top of aspirin)negative
Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990UFH, warfarincontrol (on top of aspirin)negative
Theroux (heparin vs PBO), 1988UFHplacebosuggesting
RISC (heparin vs PBO), 1990UFHplacebonegative
Theroux (heparin+aspirin vs PBO), 1988UFH + aspirinplacebosuggesting
RISC (ASP+ heparin vs PBO), 1990UFH + aspirinplacebosuggesting
Gurfinkel (UFH+aspririn vs aspirin), 1995UFHplacebo (on top of aspirin)negative
Cohen (ATACS pilot) (heparin vs asp), 1990UFH, warfarinaspirinnegative
vorapaxar
TRACER, 2011vorapaxarplacebo (on top standard therapy) NCT00527943Low risk of bias -
warfarin
ATACS (pilot study) (warfarin vs control), 1990warfarincontrol (on top of aspirin)negative
ATACS, 1994warfarincontrol (on top of aspirin)negative
CARS, 1997warfarincontrol (on top of aspirin)negative
OASIS Pilot (phase 1), 1998warfarincontrol (on top of aspirin)negative
OASIS Pilot (phase 2), 1998warfarincontrol (on top of aspirin)negative
OASIS-2 Warfarin Substudy, 2001warfarincontrol (on top of aspirin)negative
APRICOT-2, 2002warfarincontrol (on top of aspirin)negative
CHAMP, 2002warfarincontrol (on top of aspirin)negative
WARIS, 2002warfarincontrol (on top of aspirin)suggesting
LoWASA, 2004warfarincontrol (on top of aspirin)negative
Zibaeenezhad, 2004warfarincontrol (on top of aspirin)negative
Williams, 1997warfarinplacebo (on top of aspirin)negative
Huyhn, 2001warfarinplacebo (on top of aspirin)negative
ATACS (pilot study) warfarin vs aspirin, 1990warfarinaspirinnegative
ximelagatran
ESTEEM, 2003ximelagatranplaceboExploratory -

acute myocardial infarction

argatroban
ARGAMI-2, 1998Argatrobanheparin -
bivalirudin
HERO, 1997bivalirudinheparinExploratory suggesting
coumadin
ASPECT-2 (coumadin+ASA vs ASA), 2002coumadincontrol (on top of aspirin)negative
ASPECT, 1994coumadinplacebosuggesting
ASPECT-2 (coumadin alone), 2002coumadinaspirinsuggesting
dalteparin
FRAMI, 1997Dalteparinplacebo -
BIOMACS II, 1999Dalteparinplacebo -
ASSENT Plus, 2003DalteparinUFHnegative
enoxaparin
AMI-SK, 2002Enoxaparinplacebo -
ASSENT 3, 2001EnoxaparinUFHsuggesting
HART II, 2001EnoxaparinUFHnegative
Baird, 2002EnoxaparinUFHnegative
ENTIRE-TIMI 2, 2002EnoxaparinUFHsuggesting
ASSENT 3 Plus, 2003EnoxaparinUFHnegative
fondaparinux
MICHELANGELO OASIS-6, 2006fondaparinuxplaceboNCT00064428Low risk of bias suggesting
hirudin
HIT-4, 1999HirudinheparinExploratory -
TIMI 9B, 1996HirudinheparinRisk of bias -
reviparin
CREATE, 2005Reviparinplacebo -
UFH
ISIS-2 Pilot, 1987UFHno heparinnegative
DUCCS, 1994UFHno heparinnegative
ECSG, 1992UFHplacebonegative
OSIRIS, 1992UFHplacebonegative
warfarin
APRICOT-2, 2002warfarincontrol (on top of aspirin)suggesting
Zibaeenezhad, 2004warfarincontrol (on top of aspirin)negative
WARIS, 1999warfarincontrol (on top of aspirin) -
CHAMP, 2002warfarincontrol (on top of aspirin)negative
CARS (warafrin 3mg), 1997warfarincontrol (on top of aspirin)suggesting
LoWASA, 2004warfarincontrol (on top of aspirin)Risk of bias suggesting
CARS (warfarin 1mg), 1997warfarincontrol (on top of aspirin)negative
WARIS II (warfarin+ASA), 2002warfarincontrol (on top of aspirin)suggesting
Williams, 1997warfarinplacebo (on top of aspirin)suggesting
WARIS II (warfarin alone), 2002warfarinaspirinsuggesting

atrial fibrillation

apixaban
AVERROES, 2011apixabanaspirinineligible for VKANCT00496769Low risk of bias suggesting
ARISTOTLE, 2011apixabanwarfarin standard doseNCT00412984Low risk of bias conclusive
phase 2 apixabanapixabanwarfarin standard doseNCT00787150Exploratory -
aspirin
LASAF(aspirin vs no treatment), 1999aspirincontrol -
AFASAK (aspirin vs placebo), 1989aspirinplaceboLow risk of bias negative
SPAF (aspirin,warfarin ineligible arm), 1991aspirinplaceboineligible for VKALow risk of bias negative
SPAF (aspirin , warfarin eligible arm), 1991aspirinplaceboLow risk of bias suggesting
EAFT, 1993aspirinplacebonegative
FFAACS , 2001aspirinplacebo (on top fluidione)negative
PATAF (vs coumadin low dose), 1999aspirincoumadin low doseRisk of bias negative
PATAF (vs coumadin standard dose), 1999aspirincoumadin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin low dose), 1998aspirinwarfarin low doseRisk of bias negative
SPAF II (aspirin vs warfarin standard dose, age<75), 1994aspirinwarfarin standard doseRisk of bias negative
AFASAK II (aspirin vs warfarin standard dose), 1998aspirinwarfarin standard doseRisk of bias negative
SPAF II (aspirin vs warfarin standard dose, age>75), 1994aspirinwarfarin standard doseRisk of bias negative
AFASAK (aspirin vs warfarin standard dose), 1989aspirinwarfarin standard doseRisk of bias negative
BAFTA (aspirin vs warfarin standard dose) ongoing aspirinwarfarin standard dose ongoing
clopidogrel
ACTIVE W, 2006aspirin + clopidogrelanticoagulantNCT00243178Risk of bias suggesting
ACTIVE A, 2009aspirin + clopidogrelaspirinNCT00249873Low risk of bias suggesting
coumadin
PATAF (coumadin low dose vs coumadin standard dose), 1999coumadin low dosecoumadin standard doseRisk of bias negative
dabigatran
RE-LY 110mg (2nd prevention subgroup) , 2010dabigatran 100mgwarfarinExploratory suggesting
RE-LY 150mg (2nd prevention subgroup) dabigatran 150mgwarfarinExploratory suggesting
phase 2 dabigatrandabigatranwarfarin standard doseNCT01136408Exploratory -
RE-LY (110mg), 2009dabigatran 110mgwarfarin standard doseNCT00262600Risk of bias suggesting
PETRO (150mg), 2007dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009dabigatran 150mgwarfarin standard doseNCT00262600Risk of bias suggesting
edoxaban
Weitz (edoxaban phase 2)edoxabanwarfarin standard doseNCT00504556Exploratory -
phase 2 edoxabanedoxabanwarfarin standard doseNCT00806624Exploratory -
ENGAGE-AF TIMI 48 High dose, 2013edoxaban high dosewarfarin standard doseNCT00781391Low risk of bias suggesting
idraparinux
AMADEUS, 2008idraparinuxwarfarin standard doseNCT00070655Risk of bias negative
idraparinux BOREALIS-AF ongoing idraparinuxwarfarin standard doseNCT00580216 ongoing
rivaroxaban
ROCKET (2nd prevention subgroup) , 2011rivaroxabanwarfarinnegative
ROCKET-AF, 2010rivaroxabanwarfarin standard doseNCT00403767Low risk of bias suggesting
ROCKET J ongoing rivaroxabanwarfarin standard doseNCT00494871 ongoing
triflusal
NASPEAF (triflusal vs coumadin standard dose)), 2004triflusalcoumadin standard doseRisk of bias negative
warfarin
BAATAF (warfarin vs no treatment), 1990warfarin low dosecontrolNCT00000517Risk of bias suggesting
SAFT(warfarin low dose + aspirin vs no treatment), 2003warfarin low dose + aspirincontrolRisk of bias negative
AFASAK (warfarin standard dose vs control), 1989warfarin standard dosecontrolRisk of bias suggesting
SPAF (warfarin standard dose), 1991warfarin standard dosecontrolRisk of bias suggesting
SPINAF (warfarin vs placebo), 1992warfarin low doseplaceboLow risk of bias negative
CAFA, 1991warfarin standard doseplaceboLow risk of bias negative
AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998warfarin + aspirinwarfarin standard doseRisk of bias negative
SPAF III, 1996warfarin + aspirinwarfarin standard doseRisk of bias -
AFASAK II (warfarin low dose vs warfarin standard dose), 1998warfarin low dosewarfarin standard doseRisk of bias negative
MWNAF, 1998warfarin low dosewarfarin standard doseRisk of bias negative
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005ximelagatranwarfarin standard doseLow risk of bias suggesting

DVT prophylaxis

acenocoumarol
Hamulyak, 1994AcenocoumarolNadroparinnegative
Samama, 2001AcenocoumarolReviparinnegative
van Geloven, 1977Acenocoumarolunfractionated heparin -
apixaban
ADOPT, 2011apixabanenoxaparinNCT00457002suggesting
CV185-027 ongoing apixabanplaceboNCT00320255 ongoing
ADVANCE 3, 2010apixabanenoxaparinNCT00423319Low risk of bias suggesting
ADVANCE 2, 2010apixabanenoxaparin (europe regimen)NCT00452530Low risk of bias suggesting
APROPOS 2.5mg, 2007apixabanenoxaparin (US regimen)NCT00097357Exploratory negative
ardeparin
Levine, 1996ardeparinplacebosuggesting
Heit, 2000out of hospital Ardeparinstandard prophylaxisnegative
Godwin, 1993ardeparinunfractionated heparin -
aspirin
Clagett, 1975aspirincontrolRisk of bias -
Zekert VI, 1982aspirincontrolRisk of bias -
Pasteyer, 1977Aspirinno treatmentExploratory negative
Rocha, 1986Aspirinno treatmentExploratory suggesting
PEP hip-fracture, 2000aspirinplaceboLow risk of bias suggesting
Stockholm-I, 1975AspirinplaceboExploratory negative
Harris-I, 1977AspirinplaceboLow risk of bias suggesting
McKenna-I, 1980AspirinplaceboExploratory suggesting
Sautter, 1983AspirinplaceboExploratory suggesting
McBride, 1983AspirinplaceboExploratory negative
Zekert-I , 1974AspirinplaceboExploratory suggesting
Powers , 1976AspirinplaceboExploratory suggesting
Erfurt-B , 1979AspirinplaceboExploratory negative
MRC, 1972aspirinplaceboLow risk of bias negative
Loew DVT, 1974aspirinplaceboLow risk of bias -
Erfurt-A, 1979aspirinplaceboLow risk of bias -
Zekert V, 1980aspirinplaceboLow risk of bias -
Vinazzer I, 1980aspirinplaceboLow risk of bias -
Vinazzer II, 1977aspirinplaceboLow risk of bias -
PEP elective arthroplasty, 2000aspirinplaceboLow risk of bias -
betrixaban
APEX, 2016betrixabanenoxaparinNCT01583218suggesting
candesartan
Ericksson, 1997desirudinenoxaparin -
REVASC, 1997desirudinUFH -
Eriksson, 1996desirudinUFH -
Certoparin
Kock, 1995certoparincontrolRisk of bias negative
CERTIFY, 2010certoparinUFH -
Schmitz-Huebner, 1984certoparinunfractionated heparinnegative
Sasahara, 1986certoparinunfractionated heparinsuggesting
Voigt, 1986certoparinunfractionated heparinnegative
Welzel, 1988certoparinunfractionated heparinsuggesting
Kakkar, 1989certoparinunfractionated heparinnegative
Adolf, 1989certoparinunfractionated heparinnegative
Heilmann, 1989certoparinunfractionated heparinnegative
Baumgartner, 1989certoparinunfractionated heparinnegative
Hoffmann and Largiade, 1990certoparinunfractionated heparinnegative
Koppenhagen, 1990certoparinunfractionated heparin -
Schielke, 1991certoparinunfractionated heparin -
Koppenhagen, 1992certoparinunfractionated heparin -